Back to Search
LOUIS FEHRENBACHER, MD
MD
Hematology & Oncology Physician
NPI: 1942388764Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A26052(CA)
Research & Publications (20)
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
PMID 19414665·J Clin Oncol·2009
3-trial
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
PMID 19204194·J Clin Oncol·2009
3-trial
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
PMID 18640933·J Clin Oncol·2008
4-observational
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
PMID 18390971·J Clin Oncol·2008
3-trial
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
PMID 18332472·J Clin Oncol·2008
4-observational
Chemotherapy for brain metastases in small-cell lung cancer.
PMID 18282356·Clin Lung Cancer·2008
3-trial
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
PMID 17909199·J Clin Oncol·2007
3-trial
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
PMID 17618407·Invest New Drugs·2007
3-trial
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
PMID 17470851·J Clin Oncol·2007
2-rct
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
PMID 17308271·J Clin Oncol·2007
4-observational
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
PMID 16754727·JAMA·2006
4-observational
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
PMID 16737553·Breast Cancer Res·2006
8-other
Use of raloxifene among women with a history of breast cancer.
PMID 16319985·Breast Cancer Res Treat·2006
8-other
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
PMID 16258083·J Clin Oncol·2005
4-observational
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
PMID 16236738·N Engl J Med·2005
3-trial
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
PMID 16118771·J Surg Oncol·2005
8-other
Organizational barriers to physician participation in cancer clinical trials.
PMID 16044978·Am J Manag Care·2005
8-other
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
PMID 16043829·J Clin Oncol·2005
3-trial
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
PMID 15908660·J Clin Oncol·2005
3-trial
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
PMID 15897552·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 975 SERENO DR
VALLEJO, CA 94589 - Phone
- (707) 651-1000
Quick Facts
- NPI
- 1942388764
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile